A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice

Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02545465

Acronym

CAPTURE

Enrollment

125

Registered

2015-09-10

Start date

2015-09-15

Completion date

2016-08-31

Last updated

2017-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pulmonary

Keywords

Pulmonary Arterial Hypertension, Inoperable Chronic Thromboembolic Pulmonary Hypertension, Persistent Chronic Thromboembolic Pulmonary Hypertension, Recurrent Chronic Thromboembolic Pulmonary Hypertension, Switch of therapy, Titration phase, Retrospective chart review

Brief summary

The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice. In addition, this study will describe patient demographics and reason for switching

Interventions

DRUGRiociguat (Adempas, BAY63-2521)

As per the treating physicians discretion

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas

Exclusion criteria

* Patients participating in an investigational program with interventions outside of routine clinical practice * Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy

Design outcomes

Primary

Measure	Time frame
Starting Dose	Up to a total of 8 weeks of titration period
Dose Increments	Up to a total of 8 weeks of titration period
Final Dose	Up to a total of 8 weeks of titration period

Countries

Belgium, Canada, Colombia, Germany, Japan, Sweden, Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026